Yet, with respect to intrinsic TKI-resistance, several reports have shown only a marginal, not always significant, negative effect of TP53 co-mutations on the OR of gefitinib- or erlotinib-treated EGFRM+ NSCLC-patients [51,52,53,117,118]. This evidence concerns the gene TP53 and non-small cell lung carcinoma.